[go: up one dir, main page]
Jump to content

Niraparib

From Wikipedia, the free encyclopedia
(Redirected from Zejula)

Niraparib
Clinical data
Pronunciation/nɪˈræpərɪb/
nih-RAP-uh-rib
Trade namesZejula
Other namesMK-4827
AHFS/Drugs.comMonograph
MedlinePlusa617007
License data
Pregnancy
category
  • AU: D
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability73%
Protein binding83%
MetabolismCarboxylesterases
MetabolitesM1 (carboxylic acid)
Elimination half-life36 hours
Excretion48% urine, 29% feces
Identifiers
  • 2-[4-[(3S)-3-Piperidyl]phenyl]indazole-7-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.210.548 Edit this at Wikidata
Chemical and physical data
FormulaC19H20N4O
Molar mass320.396 g·mol−1
3D model (JSmol)
Solubility in water0.7–1.1
  • c1cc2cn(nc2c(c1)C(=O)N)c3ccc(cc3)[C@@H]4CCCNC4
  • InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1
  • Key:PCHKPVIQAHNQLW-CQSZACIVSA-N

Niraparib, sold under the brand name Zejula, is an anti-cancer medication used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer.[3][4][5] It is taken by mouth.[3][4] It is a PARP inhibitor.

The most common side effects include nausea (feeling sick), thrombocytopenia (low blood platelet counts), tiredness and weakness, anemia (low red blood cell counts), constipation, vomiting, abdominal (belly) pain, neutropenia (low levels of neutrophils, a type of white blood cell), insomnia (difficulty sleeping), headache, lack of appetite, diarrhea, dyspnea (difficulty breathing), hypertension (high blood pressure), back pain, dizziness, cough, joint pain, hot flushes and decrease in white blood cells.[4]

Niraparib was approved for medical use in the United States and in the European Union in 2017.[4][6][7]

Medical uses

[edit]

Niraparib is indicated for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.[5]

In October 2019, the indication for niraparib was expanded to include people with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD)-positive status.[8] HRD is defined by either a deleterious or suspected deleterious BRCA mutation, or genomic instability in patients with disease progression greater than six months after response to the last platinum-based chemotherapy.[8]

In April 2020, the indication for niraparib was expanded to include the maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.[9]

In the European Union, niraparib is indicated: as monotherapy for the maintenance treatment of adults with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy; and as monotherapy for the maintenance treatment of adults with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.[4]

Contraindications

[edit]

No contraindications are listed in the prescribing information.[3]

Side effects

[edit]

The most common side effects in studies were low blood cell counts, namely thrombocytopenia (in 61% of patients, severe in 29%), anemia (in 50%, severe in 25%) and neutropenia (in 30%, severe in 20%). Other, mostly mild to moderate side effects included nausea, fatigue, and constipation. In a study running over 250 days (median), 15% of patients had to permanently discontinue niraparib due to adverse effects.[3]

Interactions

[edit]

No clinical interaction studies have been performed. The potential for interactions with other drugs is low as niraparib and its main metabolite M1 do not significantly interact with any of the important cytochrome P450 liver enzymes in vitro. Niraparib, but not M1, is transported by P-glycoprotein and BCRP, but does not significantly inhibit them. Neither niraparib nor M1 significantly interact with any of the other important transporter proteins.[3]

Pharmacology

[edit]

Mechanism of action

[edit]
Further information: PARP inhibitor § Mechanism of action

Niraparib is an inhibitor of the enzymes PARP1 and PARP2.[10]

Pharmacokinetics

[edit]
The inactive main metabolite M1 is the carboxylic acid derivative of niraparib.[11]

73% of ingested niraparib is absorbed in the gut,[12] and it reaches highest blood plasma concentrations after about three hours, independently of food intake. In the circulation, 83% of the substance are bound to plasma proteins. It is inactivated by carboxylesterases to the main metabolite M1, the carboxylic acid derivative,[11] which is subsequently glucuronidated.[3]

The mean biological half-life is 36 hours. 47.5% of the substance are found in the urine and 38.8% in the feces. Unmetabolised niraparib accounts for 11% in the urine and 19% in the feces.[11]

Chemistry

[edit]

The drug is used in form of the salt niraparib tosylate monohydrate, which is white to off-white, non-hygroscopic crystals.[3][10]

Studies

[edit]

A 2012 study in a cell line found that PARP inhibitors exhibit cytotoxic effects not based solely on their enzymatic inhibition of PARP, but by their trapping of PARP on damaged DNA, and the strength of this trapping activity was ordered niraparib >> olaparib >> veliparib.[13]

History

[edit]

Niraparib was granted fast track designation by the US Food and Drug Administration (FDA), and Tesaro submitted a new drug application in 2016.[14] It was approved on 27 March 2017 in the US,[5] and approved in European Union on 16 November 2017.[15]

In a study with 553 patients, progression-free survival (PFS) for patients with a deleterious or suspected deleterious BRCA mutation in the germline was 21.0 months under niraparib therapy, as compared to 5.5 months under placebo. Patients without such a mutation had a PFS of 9.3 months under niraparib versus 3.9 months under placebo.[5][16]

The US Food and Drug Administration (FDA) granted the application for niraparib fast track, priority review, breakthrough therapy, and orphan drug designations.[5]

References

[edit]
  1. ^ "Summary Basis of Decision (SBD) for Zejula". Health Canada. 23 October 2014. Retrieved 29 May 2022.
  2. ^ "Zejula 100 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). Retrieved 17 January 2021.
  3. ^ a b c d e f g h "Zejula- niraparib capsule". DailyMed. Retrieved 17 January 2021.
  4. ^ a b c d e f "Zejula EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 17 January 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  5. ^ a b c d e "Niraparib (Zejula)". U.S. Food and Drug Administration (FDA). 30 March 2017. Public Domain This article incorporates text from this source, which is in the public domain.
  6. ^ "FDA approves maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers". U.S. Food and Drug Administration (FDA) (Press release). 27 March 2017. Retrieved 17 January 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  7. ^ "Drug Trials Snapshots: Zejula". U.S. Food and Drug Administration (FDA). 27 March 2017. Retrieved 17 January 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  8. ^ a b "FDA approves niraparib for HRD-positive advanced ovarian cancer". U.S. Food and Drug Administration (FDA). 23 October 2019. Retrieved 17 January 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  9. ^ "FDA approves niraparib for first-line maintenance of advanced ovarian". U.S. Food and Drug Administration (FDA). 29 April 2020. Retrieved 17 January 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  10. ^ a b "Niraparib Monograph for Professionals". American Society of Health-System Pharmacists. 22 September 2020. Retrieved 17 January 2021.
  11. ^ a b c van Andel L, Zhang Z, Lu S, Kansra V, Agarwal S, Hughes L, et al. (December 2017). "14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer". Investigational New Drugs. 35 (6): 751–765. doi:10.1007/s10637-017-0451-2. PMC 5694528. PMID 28303528.
  12. ^ van Andel L, Rosing H, Zhang Z, Hughes L, Kansra V, Sanghvi M, et al. (January 2018). "14C-microtracer and therapeutic dose in cancer patients". Cancer Chemotherapy and Pharmacology. 81 (1): 39–46. doi:10.1007/s00280-017-3455-x. PMC 5754411. PMID 29043410.
  13. ^ Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. (November 2012). "Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors". Cancer Research. 72 (21): 5588–99. doi:10.1158/0008-5472.CAN-12-2753. PMC 3528345. PMID 23118055.
  14. ^ "Niraparib Receives FDA Fast Track Designation for the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". The European Society for Medical Oncology (ESMO). 5 September 2016.
  15. ^ "Zejula". European Medicines Agency. 17 September 2018. Archived from the original on 9 August 2018. Retrieved 29 May 2018.
  16. ^ Adams B (29 June 2016). "Tesaro's PARP ovarian cancer drug hits PhIII goal; prepares to file". Fierce Biotech.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Niraparib&oldid=1234775343"